Company / Financials
Monte Rosa Therapeutics, Inc. Financials
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
-
FY2024
Net Income
-$72.7M
FY2024 · +46.3% YoY
Profit Margin
-
FY2024 · net income / revenue
ROE
-32.6%
FY2024 · return on equity
Total Assets
$438.7M
FY2024
Total Debt
-
FY2024
Equity
$222.9M
FY2024
ROA
-16.6%
FY2024 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Net Income HistoryProfit after all expenses and taxes-$72.7M+46.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$81.1M+43.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$35.2M+9.8% YoYR&D Expense HistoryResearch and development spending$121.6M+9.2% YoYIncome Tax HistoryTotal income tax expense$2.6M+660.4% YoYShares Outstanding HistoryWeighted average diluted shares outstanding73.9M+43.8% YoYTotal Assets HistoryTotal value of all assets owned$438.7M+44.4% YoYShareholders' Equity HistoryTotal assets minus total liabilities$222.9M+24.4% YoYCash & Equivalents HistoryCash and short-term liquid investments$224.3M+75.1% YoYCurrent Assets HistoryAssets expected to be converted to cash within one year$377.4M+59.8% YoY